Twitter Beğeni Hilesi

5yr outcomes of Checkmate-9LA (gosh, how time flies) Confirms better activity of dual immunotherapy in PD-L1 -ve population 22% 5yr OS is impressive in this poorer prognosis subgroup Abstract 8560 #ASCO24 #LCSM

Miss #ASCO24 or just didn’t make every education session you wanted to see? Check out the #ASCOEdBook articles from the session faculty, they are free for everyone even if you didn’t attend!

Amazing opening of the DZL Annual Meeting and warm welcome to our new SAB Member Charles Powell from the Lung Cancer Group! Charles A. Powell MD #lcsm

Happy to share the study concept of the MDT-BRIDGE study: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Eithe... sciencedirect.com/science/articl… Martin Reck Nicolas Girard Jonathan Spicer MD PhD

Thanks to Stephen V Liu, MD and Dr Anne-Marie Baird for an amazing program on management of SCLC! Managing Extensive-Stage SCLC in the Real-World: Sharing Clinician and Patient Perspectives medscape.org/viewarticle/10… via Medscape Education

Very sad news! SKYSCRAPER-06: tiragolumab plus Atezo and chemotherapy did not meet the primary endpoints of PFS and OS vs CT-Pembro. #LCSM. roche.com/investors/upda…

Thank you for the privilege to present the Five Year Outcomes of the CheckMate9LA trial ASCO ! Some years ago we never thought of 5 year OS in particular not in PD-1 negative tumors! OncLive.com onclive.com/view/five-year… via @onclive

📣 The new ESMO Living Guideline on Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer is now online. 🔗 ow.ly/aWHx50SBy3O

🔬 #ASCO2024 Insight: Prof Martin Reck & Prof Christophe Dooms discuss 5-year outcomes of the CheckMate 9LA study. Nivolumab + ipilimumab + chemo shows significant survival benefits in mNSCLC, especially with PD-L1 expression 1% or squamous histology.

Just out! Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-… #lcsm

🫁 ES-SCLC 🫁 📌 5-year survival outcomes inIMpower133 and IMbrella a extension study. 🌟 5-year OS rate 12% 📣 Martin Reck Stephen V Liu, MD Lung Cancer Journal #SCLC

Just out! Thanks for an outstanding cooperation! Stephen V Liu, MD Lung Cancer Journal #LCSM Five-year survival in patients with extensive-stage small cell lung ca... sciencedirect.com/science/articl…

Five-year survival in patients with extensive-stage #SCLC treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. 3y OS rate 16% 4y OS 13% 5y OS 12% 🚨OncoAlert🚨 Stephen V Liu, MD Martin Reck #LCSM lungcancerjournal.info/article/S0169-…

Great meeting, thank you for the invitation!

Just out! thank you for a great cooperation! Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cy... sciencedirect.com/science/articl… Oncology Advance #LCSM Luis Paz-Ares

Tune in to hear more from Dr. Martin Reck (Martin Reck), as he presents the 5yr update of CheckMate 9LA & exploratory analysis of efficacy in pts who discontinued treatment due to TRAEs in pts w/ metastatic non-small #LungCancer. #lcsm onclive.com/view/five-year…

🫁 What are the implications of the 5-year OS data from IMpower133 and the IMbrella A extension study? 💡Don't miss this interview with Martin Reck, who shares his insights on the data from the recent Lung Cancer Journal publication. ➡️ Watch: buff.ly/4dSEabu #SCLC #lcsm

👉 Already registered for the ESMO Congress 2024? Delegates can view and download the contents of the Virtual Congress Bag.🌐 Get your congress bag today! #ESMO24 🔗 ow.ly/akGU50TggFh